Publication: HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)
Issued Date
2011-09-01
Resource Type
ISSN
17921015
17920981
17920981
Other identifier(s)
2-s2.0-79960267925
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-770
Suggested Citation
Kiyoshi Kikuchi, Hisaaki Uchikado, Naoki Miura, Yoko Morimoto, Takashi Ito, Salunya Tancharoen, Kei Miyata, Rokudai Sakamoto, Chiemi Kikuchi, Narumi Iida, Naoto Shiomi, Terukazu Kuramoto, Naohisa Miyagi, Ko Ichi Kawahara HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review). Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-770. doi:10.3892/etm.2011.310 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/11484
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)
Abstract
Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB1 plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant.